| Literature DB >> 24419736 |
Kathleen W Zhang1, Benjamin French, Abigail May Khan, Ted Plappert, James C Fang, Nancy K Sweitzer, Barry A Borlaug, Julio A Chirinos, Martin St John Sutton, Thomas P Cappola, Bonnie Ky.
Abstract
BACKGROUND: The utility of longitudinal, circumferential, and radial strain and strain rate in determining prognosis in chronic heart failure is not well established. METHODS ANDEntities:
Keywords: echocardiography; heart failure; strain
Mesh:
Year: 2014 PMID: 24419736 PMCID: PMC3959676 DOI: 10.1161/JAHA.113.000550
Source DB: PubMed Journal: J Am Heart Assoc ISSN: 2047-9980 Impact factor: 5.501
Baseline Characteristics; All Summaries Presented as Median (25th and 75th percentile) Unless Otherwise Noted as n (%)
| Entire Cohort (n=416) | |
|---|---|
|
| |
| Age, y | 56 (45, 65) |
| Male, n (%) | 254 (61) |
| Race, n (%) | |
| Caucasian | 301 (72) |
| African American | 98 (24) |
| Other | 17 (4) |
|
| |
| History of hypertension, n (%) | 207 (50) |
| History of diabetes, n (%) | 115 (28) |
| Tobacco use, n (%) | |
| Never | 171 (41) |
| Former | 211 (51) |
| Current | 34 (8) |
|
| |
| NYHA functional classification, n (%) | |
| I | 57 (14) |
| II | 170 (41) |
| III | 143 (34) |
| IV | 46 (11) |
| Ischemic etiology, n (%) | 101 (24) |
| Cardiac resynchronization therapy, n (%) | 97 (23) |
| Defibrillator, n (%) | 166 (40) |
|
| |
| ACE inhibitor or ARB, n (%) | 353 (85) |
| Aldosterone antagonist, n (%) | 152 (37) |
| Beta‐blocker, n (%) | 355 (85) |
| Diuretics, n (%) | 333 (80) |
|
| |
| Body surface area, m2 | 2.0 (1.8, 2.2) |
| Systolic blood pressure, mm Hg | 108 (96, 124) |
| Diastolic blood pressure, mm Hg | 68 (60, 76) |
| Heart rate, beats/min | 74 (64, 84) |
| eGFR, mL/min per 1.73 m2 | 69 (51, 85) |
|
| |
| Longitudinal strain, % | −8.2 (−10.8, −5.7) |
| Circumferential strain, % | −11.1 (−16.8, −7.1) |
| Radial strain, % | 14.9 (9.4, 22.4) |
| Longitudinal strain rate, 1/s | −0.48 (−0.65, −0.34) |
| Circumferential strain rate, 1/s | −0.70 (−1.08, −0.49) |
| Radial strain rate, 1/s | 0.88 (0.58, 1.22) |
| Ejection fraction, % | 26 (20, 36) |
| LV end‐diastole volume/BSA, mL/m2 | 115 (88, 150) |
| LV end‐systole volume/BSA, mL/m2 | 85 (58, 118) |
| LV mass/BSA, g/m2 | 129 (104, 156) |
| Effective arterial elastance (Ea), mm Hg/mL | 1.63 (1.26, 2.12) |
| End systolic elastance (Eessb), mm Hg/mL | 0.85 (0.61, 1.27) |
| Ventricular‐arterial coupling (Ea/Eessb) | 1.92 (1.47, 2.50) |
ACE indicates angiotensin converting enzyme; ARB, angiotensin receptor blockers; BSA, body surface area; eGFR, estimated glomerular filtration rate; LV, left ventricular; NYHA, New York Heart Association.
Summary Statistics for Echocardiography‐Derived Parameters by NYHA Functional Classification, Presented as Median (25th, 75th percentile), and Spearman Rank Correlation With NT‐proBNP
| Echocardiographic Parameter | NYHA Functional Classification | Correlation With NT‐proBNP | |||
|---|---|---|---|---|---|
| I (n=57) | II (n=170) | III (n=143) | IV (n=46) | ||
| Longitudinal strain, % | −10.9 (−13.0, −9.1) | −8.8 (−11.3, −6.8) | −6.8 (−9.1, −4.9) | −6.1 (−7.8, −4.2) | 0.53 |
| Circumferential strain, % | −16.4 (−19.7, −12.4) | −12.3 (−17.5, −7.7) | −9.3 (−14.1, −6.4) | −7.7 (−9.5, −5.3) | 0.46 |
| Radial strain, % | 22.2 (16.8, 27.9) | 16.1 (11.4, 23.8) | 12.1 (7.9, 17.5) | 9.6 (5.5, 16.0) | −0.43 |
| Longitudinal SR, 1/s | −0.63 (−0.71, −0.51) | −0.51 (−0.70, −0.39) | −0.41 (−0.54, −0.32) | −0.39 (−0.55, −0.29) | 0.45 |
| Circumferential SR, 1/s | −1.00 (−1.36, −0.72) | −0.77 (−1.17, −0.51) | −0.61 (−0.87, −0.44) | −0.52 (−0.71, −0.41) | 0.44 |
| Radial SR, 1/s | 1.15 (0.84, 1.48) | 0.94 (0.64, 1.24) | 0.74 (0.52, 1.02) | 0.68 (0.44, 1.08) | −0.41 |
| Ejection fraction, % | 36 (27, 42) | 28 (22, 36) | 24 (18, 32) | 20 (18, 27) | −0.40 |
NT‐proBNP indicates N‐terminal pro‐hormone of brain natriuretic peptide; NYHA, New York Heart Association; SR, strain rate.
All P values from Kruskal‐Wallis rank sum test <0.001.
All P values <0.001.
Figure 1.Spearman rank correlation between echocardiogram measurements: Relationships between quantitative parameters of cardiac size and function and strain and strain rate. Blue hue indicates positive correlation; red hue indicates negative correlation. Darker shading indicates more extreme correlations. Ea indicates effective arterial elastance; EDV, end‐diastolic volume; Ees, end‐systolic elastance; ESV, end‐systolic volume; LV, left ventricular.
Associations Between Echocardiography‐Derived Parameters and Risk of All‐Cause Mortality, Cardiac Transplantation, or Ventricular Assist Device Placement; Cut‐Points for Each Parameter Defined by Tertiles of its Distribution
| Echocardiographic Parameter | Unadjusted | Minimally Adjusted | Fully Adjusted | Fully Adjusted+LVEF | ||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | HR (95% CI) | HR (95% CI) | |||||
|
| <0.001 | <0.001 | 0.009 | 0.14 | ||||
| Tertile 1 | Referent | Referent | Referent | Referent | ||||
| <−9.6% | ||||||||
| Tertile 2 | 1.9 (1.2, 3.1) | 1.6 (0.94, 2.6) | 1.1 (0.64, 1.9) | 0.97 (0.55, 1.7) | ||||
| ≥−9.6% to <−6.5% | ||||||||
| Tertile 3 | 3.9 (2.5, 6.1) | 3.1 (1.9, 5.0) | 1.9 (1.1, 3.2) | 1.5 (0.79, 2.7) | ||||
| ≥−6.5% | ||||||||
|
| <0.001 | <0.001 | 0.007 | 0.19 | ||||
| Tertile 1 | Referent | Referent | Referent | Referent | ||||
| <−14.7% | ||||||||
| Tertile 2 | 1.9 (1.2, 3.1) | 1.7 (1.1, 2.8) | 1.7 (1.0, 2.8) | 1.4 (0.81, 2.6) | ||||
| ≥−14.7% to <−8.3% | ||||||||
| Tertile 3 | 3.1 (2.0, 4.8) | 2.8 (1.8, 4.4) | 2.2 (1.4, 3.7) | 1.8 (0.95, 3.4) | ||||
| ≥−8.3% | ||||||||
|
| <0.001 | <0.001 | 0.014 | 0.18 | ||||
| Tertile 1 | Referent | Referent | Referent | Referent | ||||
| ≥19.4% | ||||||||
| Tertile 2 | 1.6 (1.0, 2.6) | 1.7 (1.0, 2.8) | 1.5 (0.93, 2.5) | 1.3 (0.79, 2.3) | ||||
| ≥11.3% to <19.4% | ||||||||
| Tertile 3 | 2.9 (1.9, 4.4) | 2.7 (1.7, 4.2) | 2.0 (1.3, 3.3) | 1.6 (0.97, 2.8) | ||||
| <11.3% | ||||||||
|
| <0.001 | <0.001 | 0.022 | 0.27 | ||||
| Tertile 1 | Referent | Referent | Referent | Referent | ||||
| <−0.59 1/s | ||||||||
| Tertile 2 | 2.1 (1.3, 3.4) | 1.9 (1.2, 3.1) | 1.8 (1.0, 3.0) | 1.5 (0.85, 2.6) | ||||
| ≥−0.59 to <−0.39 1/s | ||||||||
| Tertile 3 | 3.3 (2.1, 5.2) | 2.6 (1.6, 4.2) | 2.0 (1.2, 3.4) | 1.6 (0.90, 2.9) | ||||
| ≥−0.39 1/s | ||||||||
|
| <0.001 | <0.001 | 0.006 | 0.14 | ||||
| Tertile 1 | Referent | Referent | Referent | Referent | ||||
| <−0.92 1/s | ||||||||
| Tertile 2 | 1.9 (1.2, 3.1) | 1.8 (1.1, 2.9) | 1.9 (1.1, 3.2) | 1.6 (0.92, 2.9) | ||||
| ≥−0.92 to <−0.55 1/s | ||||||||
| Tertile 3 | 3.1 (1.9, 4.8) | 2.8 (1.8, 4.4) | 2.3 (1.4, 3.8) | 1.9 (1.0, 3.6) | ||||
| ≥−0.55 1/s | ||||||||
|
| <0.001 | 0.003 | 0.11 | 0.53 | ||||
| Tertile 1 | Referent | Referent | Referent | Referent | ||||
| ≥1.10 1/s | ||||||||
| Tertile 2 | 1.5 (0.95, 2.4) | 1.3 (0.82, 2.1) | 1.1 (0.69, 1.8) | 0.97 (0.58, 1.6) | ||||
| ≥0.68 to <1.10 1/s | ||||||||
| Tertile 3 | 2.3 (1.5, 3.5) | 2.1 (1.3, 3.2) | 1.6 (0.98, 2.5) | 1.2 (0.73, 2.0) | ||||
| <0.68 1/s | ||||||||
|
| <0.001 | 0.003 | 0.031 | |||||
| Tertile 1 | Referent | Referent | Referent | |||||
| ≥32% | ||||||||
| Tertile 2 | 2.2 (1.4, 3.6) | 1.8 (1.1, 2.9) | 1.8 (1.0, 3.1) | |||||
| ≥22% to <32% | ||||||||
| Tertile 3 | 2.8 (1.7, 4.3) | 2.3 (1.4, 3.7) | 2.0 (1.2, 3.3) | |||||
| <22% | ||||||||
Minimally adjusted: Age (time‐varying), gender, race, heart failure etiology. Fully adjusted: Age (time‐varying), gender, race, heart failure etiology, height, weight, heart rate, estimated GFR, ACE inhibitor or ARB use, aldosterone antagonist use, beta‐blocker use. ACE indicates angiotensin converting enzyme; ARB, angiotensin receptor blockers; CI, confidence interval; GFR, glomerular filtration rate; HR, hazard ratio; LVEF, left ventricular ejection fraction.
Figure 2.Kaplan‐Meier survival estimates for all‐cause death, cardiac transplantation, or ventricular assist device placement. Estimates according to tertiles of longitudinal strain (A); circumferential strain (B); radial strain (C); longitudinal strain rate (D); circumferential strain rate (E); and radial strain rate (F); all P<0.001 by log‐rank test.
Figure 3.Receiver operating characteristic (ROC) curves. In comparison to EF alone, strain and EF demonstrated an improved AUC at both 1 year (0.697 versus 0.633, P=0.032) (A) and 5 years (0.700 versus 0.638, P=0.014) (B). In comparison to EF alone, strain rate and EF did not provide incremental value (0.666 versus 0.633, P=0.16) at 1 year (A) and 5 years (0.668 versus 0.638, P=0.13) (B). AUC indicates area under the ROC curve; EF, ejection fraction.